Antihypertensive treatment in patients with a history of accelerated malignant hypertension, with special reference to clinical decision-making in changing treatment.
Antihypertensive treatment in patients with a history of accelerated malignant hypertension, with special reference to clinical decision-making in changing treatment.
复制标题
有加速恶性高血压病史的患者的抗高血压治疗，特别参考改变治疗的临床决策。
DOI：
--
复制
发表时间：
1994
影响因子：
12.3
通讯作者：
Y. Dohi
中科院分区：
文献类型：
--
作者：
K. Sato;M. Kojima;Y. Dohi
对通过联合治疗控制的高血压患者可以转为单一治疗的情况进行了调查。 11 名良性期加速恶性高血压患者的长期联合抗高血压治疗停药 1 天，试图确定导致血压升高程度个体差异的因素。根据第1天血压将患者分为两组：DBP高于130 mmHg的患者为A组，DBP低于130 mmHg的患者为B组。A组患者采用马尼地平单药治疗，即使最大剂量60 mg/天也未能控制，而B组患者采用马尼地平20 mg/天控制良好。 A组患者有肾功能障碍，而B组则没有。因此，肾功能障碍似乎是预测有加速恶性高血压病史的患者是否可以减少长期联合治疗的最重要的单一因素。
Conditions under which patients with hypertension controlled by combined therapy may be able to be switched to monotherapy were investigated. Eleven patients with benign phase accelerated malignant hypertension had their long-term combination antihypertensive treatment withdrawn for 1 day in an attempt to determine factors contributing to individual variability in the extent of BP increase. Patients were divided into two groups according to BP on day 1: patients with DBP above 130 mmHg formed group A, and those with DBP below 130 mmHg formed group B. Group A patients were not controlled by monotherapy with manidipine, even at the maximal dose of 60 mg/day, while group B patients were satisfactorily controlled by manidipine 20 mg/day. Group A patients had renal dysfunction whereas those in group B did not. Thus, renal dysfunction appears to be the most important single factor in predicting whether long-term combination therapy may be reduced in patients with a history of accelerated malignant hypertension.
停止长期用药后，饮食疗法可减缓高血压的复发。
DOI：
--
发表时间：
1985
期刊：
JAMA : the journal of the American Medical Association
影响因子：
--
作者：
Langford,HG;Blaufox,MD;Oberman,A;Hawkins,CM;Curb,JD;Cutter,GR;Wassertheil-Smoller,S;Pressel,S;Babcock,C;Abernethy,JD
通讯作者：
Abernethy,JD